Biogen is still evaluating launch timeline for Tofidence, and information on pricing will be available closer to launch.
The FDA has approved Biogen’s Tofidence (tocilizumab-bavi) as first biosimilar to reference Genentech’s Actemra (tocilizumab). Tofidence is an interleukin-6 (IL-6) receptor antagonist that targets specific inflammatory proteins to suppress the immune system.
Tofidence is approved to treat rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis in patients ages 2 and older, and systemic juvenile idiopathic arthritis in patients ages 2 and older. Tofidence, previously known as BIIB800, is administered via intravenous infusion.
“The approval of Tofidence in the U.S. marks another positive step toward helping more people with chronic autoimmune conditions gain access to leading therapies,” Ian Henshaw, global head of biosimilars at Biogen, said in a press release. “With the increasing numbers of approved biosimilars, we expect increased savings and sustainability for healthcare systems and an increase in physician choice and patient access to biologics.”
Developed by Bio-Thera, Tofidence will be commercialized by Biogen in the United States. Biogen is still evaluating launch timeline, and information on pricing will be available closer to launch, according to a spokesperson.
The FDA approval of Tofidence was based on analytical, nonclinical and clinical data submitted by Biogen in September 2022. Additionally, a phase 1 study compared the pharmacokinetics, safety and immunogenicity of Tofidence with both the U.S. and EU reference tocilizumab in healthy volunteers, and parallel phase 3 study compared Tofidence with Actemra to establish equivalent efficacy and comparable pharmacokinetic, safety and immunogenicity profiles, in subjects with rheumatoid arthritis inadequately controlled by methotrexate.
The most common side effects associated with tocilizumab products are upper respiratory tract infections, common cold, headache, hypertension, elevated liver enzymes, and injection site reactions.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More